Jump to content

Ucenprubart

From Wikipedia, the free encyclopedia
Ucenprubart
Monoclonal antibody
Type?
Clinical data
Other namesLY3454738
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Ucenprubart (LY3454738) is a monoclonal antibody that acts as an agonist at CD200R1 and is developed by Eli Lilly and Company for atopic dermatitis and other autoimmune diseases.[1][2][3][4]

References

[edit]
  1. ^ Metz, Martin; Maurer, Marcus (12 February 2021). "Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?". Allergologie Select. 5: 89–95. doi:10.5414/ALX02204E. ISSN 2512-8957. PMC 7890936. PMID 33615122.
  2. ^ Metz, Martin; Kolkhir, Pavel; Altrichter, Sabine; Siebenhaar, Frank; Levi-Schaffer, Francesca; Youngblood, Bradford A.; Church, Martin K.; Maurer, Marcus (22 August 2023). "Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases". Allergy. 79 (1): 37–51. doi:10.1111/all.15850. PMID 37605867. S2CID 261063967.
  3. ^ Maurer, Marcus; Khan, David A.; Elieh Ali Komi, Daniel; Kaplan, Allen P. (1 March 2021). "Biologics for the Use in Chronic Spontaneous Urticaria: When and Which". The Journal of Allergy and Clinical Immunology: In Practice. 9 (3): 1067–1078. doi:10.1016/j.jaip.2020.11.043. ISSN 2213-2198. PMID 33685605. S2CID 232159087.
  4. ^ "Lilly.com | Eli Lilly and Company". www.lilly.com. Retrieved 24 November 2023.